Enhanced Percutaneous Delivery of Beta-Blockers Using Thermal Resurfacing Drug Delivery System for Topical Treatment of Infantile Hemangiomas.
Administration, Topical
Adrenergic beta-Antagonists
/ administration & dosage
Drug Delivery Systems
/ instrumentation
Female
Hemangioma, Capillary
/ drug therapy
Humans
Hyperthermia, Induced
/ instrumentation
Infant
Male
Propranolol
/ administration & dosage
Retrospective Studies
Skin Neoplasms
/ drug therapy
Timolol
/ administration & dosage
Beta-blockers
Enhanced percutaneous delivery
Infantile hemangioma
Pediatric dermatology
Tixel
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
01
2020
accepted:
03
04
2020
pubmed:
13
7
2020
medline:
15
9
2021
entrez:
13
7
2020
Statut:
ppublish
Résumé
Infantile hemangiomas (IHs) are the most common vascular tumors in children. In the past few years, topical beta-blockers (bBs) have been reported to be an effective treatment of superficial IHs. We sought to evaluate the clinical effectiveness and safety profile of enhanced percutaneous delivery of bBs for the treatment of IH. A retrospective study of all cases of IHs treated with enhanced percutaneous delivery of bBs between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed. The study included 11 patients with a total of 11 IHs. Of the total number of IHs, 7 (63.7%) showed a good response to treatment and 4 (36.3%) had a partial response; thus all patients (100%) had good or partial response to treatment. No systemic or local adverse effects were reported. This is an uncontrolled retrospective study. Enhanced percutaneous delivery of bBs is a safe and efficient topical therapy for IH.
Sections du résumé
BACKGROUND
BACKGROUND
Infantile hemangiomas (IHs) are the most common vascular tumors in children. In the past few years, topical beta-blockers (bBs) have been reported to be an effective treatment of superficial IHs.
OBJECTIVE
OBJECTIVE
We sought to evaluate the clinical effectiveness and safety profile of enhanced percutaneous delivery of bBs for the treatment of IH.
METHODS
METHODS
A retrospective study of all cases of IHs treated with enhanced percutaneous delivery of bBs between 2018 and 2019 was performed. Epidemiologic, clinical, and treatment data, including effectiveness score and safety, were reviewed.
RESULTS
RESULTS
The study included 11 patients with a total of 11 IHs. Of the total number of IHs, 7 (63.7%) showed a good response to treatment and 4 (36.3%) had a partial response; thus all patients (100%) had good or partial response to treatment. No systemic or local adverse effects were reported.
LIMITATIONS
CONCLUSIONS
This is an uncontrolled retrospective study.
CONCLUSION
CONCLUSIONS
Enhanced percutaneous delivery of bBs is a safe and efficient topical therapy for IH.
Identifiants
pubmed: 32653885
pii: 000507808
doi: 10.1159/000507808
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Timolol
817W3C6175
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-570Informations de copyright
© 2020 S. Karger AG, Basel.